AI Engines For more Details: Perplexity Kagi Labs You
Diuretic Effect: Canrenoic acid potassium salt works by increasing the excretion of sodium and water from the body while retaining potassium. This helps to reduce fluid buildup in the body, leading to decreased blood volume and lower blood pressure.
Hypertension Management: It may be prescribed to help lower blood pressure in individuals with hypertension, either alone or in combination with other antihypertensive medications.
Edema Treatment: Canrenoic acid potassium salt is commonly used to treat edema associated with conditions such as congestive heart failure, liver cirrhosis, and kidney disease by promoting the removal of excess fluid from the body.
Heart Failure Management: It may be used as part of the treatment for heart failure to reduce fluid overload and alleviate symptoms such as shortness of breath and swelling.
Potassium-Sparing Action: Similar to canrenone, canrenoic acid potassium salt helps to retain potassium in the body, which is important for maintaining normal heart rhythm and muscle function.
Reduction of Aldosterone Effects: Canrenoic acid potassium salt acts as an antagonist of aldosterone, a hormone that regulates sodium and potassium balance in the body. By blocking aldosterone's effects, it helps to reduce sodium and water retention.
Management of Ascites: Canrenoic acid potassium salt may be used to manage ascites, which is the accumulation of fluid in the abdominal cavity often seen in liver cirrhosis.
Prevention of Hypokalemia: Its potassium-sparing effect helps prevent hypokalemia (low potassium levels), which can occur with other diuretics that promote potassium excretion.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 3.2 | 0.6 | 4.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.9 | 2 | 0.45 |
| Allergies | 4.3 | 1.3 | 2.31 |
| Allergy to milk products | 1.1 | 1.6 | -0.45 |
| Alopecia (Hair Loss) | 0.9 | 0.9 | |
| Alzheimer's disease | 4.9 | 3.9 | 0.26 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.6 | 1.83 |
| Ankylosing spondylitis | 3.2 | 0.7 | 3.57 |
| Anorexia Nervosa | 1.3 | 1.7 | -0.31 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 4.6 | 1.9 | 1.42 |
| Atherosclerosis | 1.7 | 0.9 | 0.89 |
| Atrial fibrillation | 2.5 | 1.9 | 0.32 |
| Autism | 5.6 | 5.5 | 0.02 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.5 | 2.5 | |
| Bipolar Disorder | 2.1 | 1.1 | 0.91 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.6 | 1.3 | -1.17 |
| Carcinoma | 4.1 | 1.7 | 1.41 |
| Celiac Disease | 1.8 | 2.3 | -0.28 |
| Cerebral Palsy | 1.4 | 1 | 0.4 |
| Chronic Fatigue Syndrome | 4.2 | 3.1 | 0.35 |
| Chronic Kidney Disease | 3.2 | 0.8 | 3 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.6 | 1.4 | 0.86 |
| Chronic Urticaria (Hives) | 2 | 0.2 | 9 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1 | 0.9 |
| Cognitive Function | 3.1 | 1.3 | 1.38 |
| Colorectal Cancer | 7.3 | 2.2 | 2.32 |
| Constipation | 1 | 0.7 | 0.43 |
| Coronary artery disease | 1.6 | 1.5 | 0.07 |
| COVID-19 | 7.2 | 6.7 | 0.07 |
| Crohn's Disease | 6.7 | 2.8 | 1.39 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 1.2 | 1.4 | -0.17 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.7 | 1.1 | 1.45 |
| Denture Wearers Oral Shifts | 1.5 | 1.5 | |
| Depression | 8.3 | 5 | 0.66 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 1.8 | 0 |
| Endometriosis | 3.2 | 1.4 | 1.29 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.1 | 1.4 | 1.21 |
| erectile dysfunction | 1.8 | 0.3 | 5 |
| Fibromyalgia | 3 | 1.1 | 1.73 |
| Functional constipation / chronic idiopathic constipation | 3.6 | 2.7 | 0.33 |
| gallstone disease (gsd) | 3.2 | 1.1 | 1.91 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 1 | 0.5 |
| Generalized anxiety disorder | 2.6 | 1.6 | 0.63 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.8 | 0.2 | 8 |
| Graves' disease | 1.3 | 2.4 | -0.85 |
| Gulf War Syndrome | 0.6 | 1.1 | -0.83 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 2.6 | 0.9 | 1.89 |
| Heart Failure | 3.1 | 1 | 2.1 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.8 | 0.3 | 5 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0 | 0 |
| hyperglycemia | 2.4 | 1.2 | 1 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 2.8 | 3.2 | -0.14 |
| Hypothyroidism | 0 | 0.7 | 0 |
| Hypoxia | 3.4 | 0.3 | 10.33 |
| IgA nephropathy (IgAN) | 1.6 | 3 | -0.88 |
| Inflammatory Bowel Disease | 7.8 | 4.3 | 0.81 |
| Insomnia | 2.1 | 1.6 | 0.31 |
| Intelligence | 1.4 | 1.4 | |
| Intracranial aneurysms | 1.1 | 0.3 | 2.67 |
| Irritable Bowel Syndrome | 6 | 3.4 | 0.76 |
| ischemic stroke | 2.3 | 1.4 | 0.64 |
| Liver Cirrhosis | 6.3 | 4.3 | 0.47 |
| Long COVID | 4.8 | 4.3 | 0.12 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 1.5 | 0.7 | 1.14 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.3 | 4 |
| ME/CFS with IBS | 0.7 | 1.4 | -1 |
| ME/CFS without IBS | 1.2 | 1.5 | -0.25 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.1 | 0.6 | 0.83 |
| Metabolic Syndrome | 5.8 | 4.9 | 0.18 |
| Mood Disorders | 7.4 | 3.7 | 1 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 5.4 | 3.1 | 0.74 |
| Multiple system atrophy (MSA) | 1 | 0.4 | 1.5 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 1.7 | -4.67 |
| Neuropathy (all types) | 0.7 | 1.6 | -1.29 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.4 | 2.1 | 1.1 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 6.4 | 5.8 | 0.1 |
| obsessive-compulsive disorder | 4.4 | 1.7 | 1.59 |
| Osteoarthritis | 2.3 | 0.9 | 1.56 |
| Osteoporosis | 2.2 | 1.3 | 0.69 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 5.9 | 4.3 | 0.37 |
| Polycystic ovary syndrome | 4.6 | 2 | 1.3 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 1.2 | 1.1 | 0.09 |
| Primary sclerosing cholangitis | 2.4 | 1.7 | 0.41 |
| Psoriasis | 2.2 | 1.4 | 0.57 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.6 | 2.8 | 0.64 |
| Rosacea | 0.3 | 1 | -2.33 |
| Schizophrenia | 3.8 | 2.2 | 0.73 |
| scoliosis | 0.6 | 0.3 | 1 |
| Sjögren syndrome | 1.8 | 2.2 | -0.22 |
| Sleep Apnea | 1.3 | 1.3 | 0 |
| Slow gastric motility / Gastroparesis | 1.2 | 0.3 | 3 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 2 | |
| Stress / posttraumatic stress disorder | 3.2 | 1.8 | 0.78 |
| Systemic Lupus Erythematosus | 3.4 | 1.2 | 1.83 |
| Tic Disorder | 0.4 | 0.9 | -1.25 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3 | 1.9 | 0.58 |
| Type 2 Diabetes | 6.2 | 5.4 | 0.15 |
| Ulcerative colitis | 5.4 | 4.3 | 0.26 |
| Unhealthy Ageing | 3.6 | 1.3 | 1.77 |
| Vitiligo | 1.5 | 0.9 | 0.67 |
